

Supplementary Material Legend

Supplemental Table 1 Overall and Gender stratified Substance use disorder and Diabetes Mellitus-related Mortality, in the United States from 1999 to 2022

Deaths			
Year	Men	Women	Overall
1999	1646	441	2087
2000	1723	492	2215
2001	1839	500	2339
2002	2024	601	2625
2003	2209	622	2831
2004	2357	706	3063
2005	2587	756	3343
2006	2748	828	3576
2007	2962	915	3877
2008	3006	859	3865
2009	3048	973	4021
2010	3304	1014	4318
2011	3422	1126	4548
2012	3683	1100	4783
2013	3888	1218	5106
2014	4156	1335	5491
2015	4459	1328	5787
2016	4863	1543	6406
2017	5436	1589	7025
2018	5773	1768	7541
2019	6314	1871	8185
2020	8115	2342	10457

2021	9185	2872	12057
2022	9255	2858	12113
Total	98002	29657	127659

Supplemental Table 2 Substance use disorder and Diabetes mellitus-related Mortality, Stratified by Race in the United States from 1999 to 2020

Deaths					
Year	NH White	NH Black or African American	NH American Indian or Alaska Native	Hispanic Or Latino	Population
1999	1244	474	59	284	180408769
2000	1382	456	61	287	181984640
2001	1475	472	51	295	184305128
2002	1642	526	84	317	186208028
2003	1735	596	95	368	188090429
2004	1927	606	83	381	190205384
2005	2100	669	97	413	192551384
2006	2232	660	120	504	195019359
2007	2459	705	140	514	197403777
2008	2506	663	119	516	199795090
2009	2538	752	137	520	202107016

2010	2756	744	134	606	203891983
2011	2891	832	143	585	206592936
2012	3101	766	178	648	208826037
2013	3217	824	173	778	211085314
2014	3552	824	186	805	213809280
2015	3685	923	211	809	216553817
2016	4095	1058	221	897	218641417
2017	4462	1152	252	963	221447331
2018	4778	1256	286	1044	223311190
2019	5193	1359	259	1213	224981167
2020	6343	1794	409	1652	226635013
Total	65313	18111	3498	14399	4473854489

NH=Non Hispanics

Supplemental Table 3 Annual percent change of Substance use disorder and Diabetes Mellitus related Age-Adjusted Mortality Rates per 1000,000 in Adults in the United States from 1999 to 2020

Year Interval	APC (95%CI)
Overall	
1999-2016	4.4*(3.6 to 5.0)
2016-2022	11.8*(10.2 to 14.5)
Male	
1999-2016	4.0*(3.3 to 4.6)
2016-2022	11.7*(9.9 to 14.1)

Female

1999-2017	5.5*(4.8 to 6.1)
2017-2022	11.8*(10.2 to 14.5)

Race**American Indian or Alaska Native**

1999-2018	5.5* (-0.7 to17.7)
2018-2020	21.7* (6.2 to31.6)

Black or African American

1999-2015	1.2* (-0.0 to 2.3)
2015-2020	11.7* (7.7 to 23.2)

White

1999-2007	7.2* (6.6 to 8.6)
2007-2010	2.0*(0.8 to 4.4)
2010-2018	6.4*(5.8 to 7.5)
2018-2020	15.7*(12.8 to17.7)

Hispanic or Latino

1999-2018	2.1*(1.4 to 2.8)
2018-2020	23.4* (13.6 to 28.9)

Urban-Rural

Metropolitan

1999-2018	4.3*(3.8 to 4.8)
2018-2020	18.4*(10.9 to 22.4)

Non metropolitan

1999-2005	8.1*(6.5 to 11.1)
2005-2013	3.4*(0.8 to 4.3)
2013-2018	8.8*(5.7 to 10.7)
2018-2020	17.6*(13.2 to 20.5)

Age groups**25-39 years**

1999-2003	8.4*(5.5 to 14.4)
2003-2011	1.7*(-2.2 to 2.8)
2011-2018	8.2*(6.6 to 9.9)
2018-2020	24.5* (19.7 to 28.0)

40-54 years

1999-2006	7.2* (5.3 to 12.7)
2006-2018	3.6*(0.0 to 4.2)

2018-2020	18.3*(10.4 to 22.8)
55-69 years	
1999-2014	5.1*(1.9 to 12.8)
2014-2018	7.8*(3.1 to 9.5)
2018-2020	15.8*(10.3 to 19.6)
70-84 years	
1999-2015	2.7*(1.7 to 3.5)
2015-2020	10.7*(7.9 to 18.7)
85+ years	
1999-2020	4.1*(3.0 to 5.6)
APC = annual percent change; NH = Non Hispanic	

Supplemental Table 4 Overall and Sex - stratified, Substance use disorder and Diabetes Mellitus-related Age-Adjusted Mortality Rates per 1000,000 in the United States from 1999 to 2020

Age-Adjusted Mortality Rate (95%CI)			
Year	Men	Women	Overall
1999	19.9	4.7	11.7
	(19.0 - 20.9)	(4.3 - 5.1)	(11.2 - 12.3)
2000	20.5	5.1	12.3
	(19.5 - 21.5)	(4.7 - 5.6)	(11.8 - 12.8)

2001	21.3 (20.3 - 22.3)	5.2 (4.7 - 5.6)	12.7 (12.2 - 13.2)
2002	22.9 (21.9 - 23.9)	6.1 (5.6 - 6.6)	14.0 (13.4 - 14.5)
2003	24.4 (23.4 - 25.4)	6.2 (5.7 - 6.7)	14.8 (14.2 - 15.3)
2004	25.4 (24.4 - 26.5)	6.9 (6.4 - 7.4)	15.7 (15.1 - 16.2)
2005	27.3 (26.2 - 28.3)	7.3 (6.8 - 7.8)	16.7 (16.1 - 17.3)
2006	28.3 (27.2 - 29.4)	7.9 (7.3 - 8.4)	17.6 (17.0 - 18.1)
2007	29.7 (28.7 - 30.8)	8.5 (8.0 - 9.1)	18.6 (18.0 - 19.2)
2008	29.6 (28.5 - 30.6)	7.9 (7.4 - 8.4)	18.2 (17.6 - 18.7)
2009	29.5 (28.4 - 30.5)	8.9 (8.3 - 9.4)	18.6 (18.0 - 19.2)
2010	31.3 (30.2 - 32.4)	9.1 (8.5 - 9.6)	19.6 (19.0 - 20.1)
2011	31.7 (30.6 - 32.8)	9.9 (9.4 - 10.5)	20.3 (19.7 - 20.9)
2012	33.4 (32.3 - 34.5)	9.6 (9.0 - 10.2)	20.9 (20.3 - 21.5)
2013	34.8 (33.6 - 35.9)	10.6 (10.0 - 11.2)	22.1 (21.4 - 22.7)
2014	36.6 (35.5 - 37.8)	11.4 (10.7 - 12.0)	23.4 (22.7 - 24.0)

2015	38.7 (37.5 - 39.8)	11.1 (10.5 - 11.7)	24.3 (23.6 - 24.9)
2016	41.5 (40.3 - 42.7)	12.6 (11.9 - 13.2)	26.4 (25.7 - 27.0)
2017	45.6 (44.4 - 46.9)	12.8 (12.2 - 13.5)	28.5 (27.8 - 29.1)
2018	47.9 (46.7 - 49.2)	14.3 (13.7 - 15.0)	30.4 (29.7 - 31.1)
2019	52.0 (50.7 - 53.4)	15.1 (14.4 - 15.8)	32.7 (32.0 - 33.5)
2020	66.9 (65.4 - 68.4)	18.6 (17.8 - 19.4)	41.7 (40.9 - 42.5)
2021	73.6 (72.0 - 75.1)	23.0 (22.1 - 23.9)	47.4 (46.6 - 48.3)
2022	73.8 (72.3 - 75.4)	22.8 (21.9 - 23.7)	47.5 (46.6 - 48.3)

Supplemental Table 5 Substance use disorder and Diabetes Mellitus -related Age-Adjusted Mortality Rates per 1000,000, Stratified by Race in Adults in the United States from 1999 to 2020

Age-Adjusted Mortality Rate (95% CI)				
Year	NH White	NH Black or African American	NH American Indian or Alaska Native	Hispanic or Latino

1999	8.9 (8.4 - 9.4)	26.3 (23.9 - 28.7)	50.5 (38.0 - 65.7)	22.9 (20.2 - 25.7)
2000	9.8 (9.3 - 10.3)	24.6 (22.3 - 26.9)	56.5 (42.6 - 73.5)	22.4 (19.7 - 25.2)
2001	10.4 (9.8 - 10.9)	24.4 (22.2 - 26.6)	44.1 (32.2 - 59.0)	21.2 (18.6 - 23.7)
2002	11.4 (10.8 - 12.0)	26.5 (24.2 - 28.8)	67.6 (53.4 - 84.4)	21.6 (19.1 - 24.1)
2003	11.9 (11.4 - 12.5)	29.3 (27.0 - 31.7)	73.9 (59.2 - 91.1)	23.0 (20.6 - 25.5)
2004	13.1 (12.5 - 13.7)	29.0 (26.6 - 31.3)	62.1 (49.1 - 77.5)	23.0 (20.6 - 25.4)
2005	14.0 (13.4 - 14.6)	30.9 (28.6 - 33.3)	69.3 (55.8 - 85.1)	24.4 (21.9 - 26.8)
2006	14.7 (14.1 - 15.3)	29.4 (27.1 - 31.6)	84.7 (69.1 - 100.3)	28.5 (25.9 - 31.1)
2007	16.0 (15.4 - 16.7)	30.6 (28.3 - 32.8)	94.6 (78.5 - 110.7)	26.9 (24.4 - 29.3)
2008	16.1 (15.4 - 16.7)	28.1 (25.9 - 30.3)	80.7 (65.7 - 95.7)	25.1 (22.8 - 27.3)
2009	16.2 (15.6 - 16.8)	31.3 (29.0 - 33.5)	93.1 (76.9 - 109.2)	25.1 (22.9 - 27.4)
2010	17.3 (16.6 - 18.0)	30.2 (28.0 - 32.4)	85.4 (70.5 - 100.3)	28.2 (25.8 - 30.5)
2011	18.1 (17.4 - 18.8)	32.5 (30.2 - 34.7)	91.6 (76.1 - 107.2)	24.7 (22.6 - 26.8)
2012	19.2 (18.5 - 19.8)	29.2 (27.1 - 31.3)	114.3 (96.9 - 131.7)	26.5 (24.4 - 28.6)

2013	19.7 (19.0 - 20.4)	31.1 (29.0 - 33.3)	106.5 (90.1 - 122.8)	31.1 (28.8 - 33.3)
2014	21.8 (21.0 - 22.5)	30.0 (27.9 - 32.1)	108.6 (92.6 - 124.6)	29.6 (27.5 - 31.7)
2015	22.2 (21.4 - 22.9)	33.1 (31.0 - 35.3)	125.0 (107.7 - 142.3)	28.8 (26.8 - 30.9)
2016	24.5 (23.7 - 25.3)	37.1 (34.8 - 39.4)	125.0 (108.1 - 141.8)	31.1 (29.0 - 33.2)
2017	26.4 (25.6 - 27.2)	39.4 (37.1 - 41.7)	146.6 (128.1 - 165.2)	31.9 (29.9 - 34.0)
2018	28.4 (27.5 - 29.2)	42.4 (40.0 - 44.8)	162.1 (142.9 - 181.4)	33.5 (31.4 - 35.6)
2019	30.8 (29.9 - 31.7)	45.5 (43.0 - 48.0)	146.0 (127.8 - 164.3)	37.4 (35.2 - 39.5)
2020	37.7 (36.8 - 38.7)	59.9 (57.1 - 62.7)	229.4 (206.5 - 252.3)	49.6 (47.2 - 52.1)

AAMR=Age Adjusted Mortality rate, NH=Non Hispanic

Supplemental Table 6 Substance use disorder and Diabetes Mellitus -related Age Adjusted Mortality Rates per 1000,000, Stratified by States in Adults in the United States from 1999 to 2020

Deaths	
State	Age-Adjusted Mortality Rate (95%CI)
Alabama	11.4 (10.6 - 12.2)
Alaska	27.4 (23.9 - 30.9)

Arizona	30.5 (29.3 - 31.6)
Arkansas	14.7 (13.6 - 15.9)
California	33.3 (32.8 - 33.8)
Colorado	31.3 (30.0 - 32.6)
Connecticut	12.5 (11.6 - 13.4)
Delaware	25.4 (22.7 - 28.0)
District of Columbia	35.4 (31.5 - 39.3)
Florida	15.3 (14.8 - 15.7)
Georgia	15.7 (15.0 - 16.3)
Hawaii	21.5 (19.5 - 23.6)
Idaho	26.0 (23.9 - 28.1)
Illinois	12.2 (11.7 - 12.7)

Indiana	17.1 (16.3 - 17.9)
Iowa	21.7 (20.3 - 23.0)
Kansas	20.3 (19.0 - 21.7)
Kentucky	27.3 (26.0 - 28.6)
Louisiana	17.0 (16.0 - 18.0)
Maine	21.4 (19.5 - 23.3)
Maryland	20.4 (19.5 - 21.3)
Massachusetts	17.7 (16.9 - 18.5)
Michigan	16.4 (15.8 - 17.1)
Minnesota	34.5 (33.2 - 35.8)
Mississippi	17.6 (16.3 - 18.8)
Missouri	14.8 (14.0 - 15.6)
Montana	31.9 (29.1 - 34.8)

Nebraska	17.4 (15.9 - 19.0)
Nevada	27.2 (25.6 - 28.8)
New Hampshire	18.2 (16.4 - 20.0)
New Jersey	12.2 (11.6 - 12.8)
New Mexico	38.3 (36.1 - 40.6)
New York	16.8 (16.3 - 17.2)
North Carolina	23.7 (22.9 - 24.5)
North Dakota	35.7 (32.0 - 39.4)
Ohio	20.2 (19.5 - 20.8)
Oklahoma	43.6 (41.9 - 45.3)
Oregon	43.0 (41.4 - 44.7)

Pennsylvania	14.6 (14.0 - 15.1)
Rhode Island	31.3 (28.7 - 34.0)
South Carolina	21.7 (20.6 - 22.8)
South Dakota	33.0 (29.8 - 36.3)
Tennessee	22.2 (21.3 - 23.1)
Texas	20.9 (20.5 - 21.4)
Utah	16.6 (15.2 - 18.0)
Vermont	39.5 (35.7 - 43.2)
Virginia	13.8 (13.1 - 14.4)
Washington	30.5 (29.4 - 31.6)
West Virginia	30.0 (28.0 - 32.0)
Wisconsin	24.8 (23.8 - 25.9)

Wyoming	34.2 (30.2 - 38.2)
----------------	-----------------------

Supplemental Table 7 Substance use disorder and Diabetes Mellitus –related Age-Adjusted Mortality Rates per 1000,000 Stratified by Census Region in Adults in the United States from 1999 to 2020

Deaths		
Census Region	Year	Age-Adjusted Mortality Rate (95% CI)
Northeast	1999	9.4 (8.4 - 10.4)
Northeast	2000	10.7 (9.6 - 11.7)
Northeast	2001	10.5 (9.5 - 11.6)
Northeast	2002	11.3 (10.2 - 12.4)
Northeast	2003	10.6 (9.5 - 11.6)
Northeast	2004	11.2 (10.1 - 12.2)

Northeast	2005	12.3 (11.2 - 13.4)
Northeast	2006	12.7 (11.6 - 13.8)
Northeast	2007	13.9 (12.7 - 15.1)
Northeast	2008	13.4 (12.3 - 14.6)
Northeast	2009	13.7 (12.5 - 14.8)
Northeast	2010	14.5 (13.3 - 15.7)
Northeast	2011	15.6 (14.4 - 16.8)
Northeast	2012	16.2 (14.9 - 17.4)

Northeast	2013	16.7 (15.4 - 17.9)
Northeast	2014	17.7 (16.4 - 18.9)
Northeast	2015	18.2 (16.9 - 19.5)
Northeast	2016	21.0 (19.6 - 22.4)
Northeast	2017	20.0 (18.7 - 21.3)
Northeast	2018	21.7 (20.2 - 23.1)
Northeast	2019	23.7 (22.2 - 25.1)
Northeast	2020	31.4 (29.7 - 33.1)
Northeast	Total	16.0 (15.8 - 16.3)

Midwest	1999	9.7 (8.8 - 10.7)
Midwest	2000	10.6 (9.6 - 11.6)
Midwest	2001	11.5 (10.5 - 12.5)
Midwest	2002	12.1 (11.0 - 13.1)
Midwest	2003	12.7 (11.6 - 13.7)
Midwest	2004	13.7 (12.6 - 14.8)
Midwest	2005	13.7 (12.6 - 14.8)
Midwest	2006	15.0 (13.9 - 16.2)

Midwest	2007	15.9 (14.7 - 17.0)
Midwest	2008	16.0 (14.9 - 17.2)
Midwest	2009	17.5 (16.3 - 18.7)
Midwest	2010	17.6 (16.4 - 18.7)
Midwest	2011	18.4 (17.1 - 19.6)
Midwest	2012	18.8 (17.5 - 20.0)
Midwest	2013	19.3 (18.0 - 20.5)
Midwest	2014	21.3 (20.0 - 22.6)
Midwest	2015	21.9 (20.6 - 23.2)

Midwest	2016	24.2 (22.8 - 25.5)
Midwest	2017	26.1 (24.7 - 27.6)
Midwest	2018	28.4 (26.9 - 29.9)
Midwest	2019	30.1 (28.6 - 31.7)
Midwest	2020	38.0 (36.3 - 39.8)
Midwest	Total	19.2 (18.9 - 19.5)
South	1999	11.2 (10.4 - 12.1)
South	2000	11.5 (10.7 - 12.3)
South	2001	11.7 (10.9 - 12.5)

South	2002	12.4 (11.5 - 13.2)
South	2003	14.2 (13.4 - 15.1)
South	2004	13.6 (12.7 - 14.4)
South	2005	14.9 (14.0 - 15.8)
South	2006	16.0 (15.1 - 16.9)
South	2007	16.6 (15.7 - 17.5)
South	2008	15.8 (14.9 - 16.7)
South	2009	15.7 (14.8 - 16.5)

South	2010	17.6 (16.7 - 18.6)
South	2011	18.2 (17.3 - 19.1)
South	2012	18.6 (17.6 - 19.5)
South	2013	19.5 (18.6 - 20.5)
South	2014	20.3 (19.3 - 21.2)
South	2015	21.0 (20.0 - 22.0)
South	2016	23.0 (22.0 - 24.0)
South	2017	26.0 (24.9 - 27.1)
South	2018	28.8 (27.7 - 29.9)

South	2019	30.5 (29.3 - 31.6)
South	2020	39.1 (37.8 - 40.4)
South	Total	19.7 (19.5 - 19.9)
West	1999	17.2 (15.8 - 18.5)
West	2000	17.1 (15.8 - 18.5)
West	2001	17.7 (16.4 - 19.0)
West	2002	21.2 (19.8 - 22.6)
West	2003	21.8 (20.4 - 23.2)
West	2004	25.3 (23.8 - 26.8)

West	2005	26.8 (25.3 - 28.4)
West	2006	27.0 (25.5 - 28.5)
West	2007	28.7 (27.1 - 30.2)
West	2008	28.3 (26.7 - 29.8)
West	2009	28.8 (27.3 - 30.3)
West	2010	29.1 (27.6 - 30.6)
West	2011	29.5 (28.0 - 31.0)
West	2012	30.9 (29.4 - 32.4)

West	2013	33.3 (31.7 - 34.9)
West	2014	35.1 (33.5 - 36.7)
West	2015	36.6 (34.9 - 38.2)
West	2016	38.2 (36.6 - 39.9)
West	2017	41.4 (39.6 - 43.1)
West	2018	41.7 (40.0 - 43.4)
West	2019	45.9 (44.1 - 47.7)
West	2020	57.2 (55.2 - 59.2)
West	Total	32.0 (31.7 - 32.4)

Total	Total	21.6 (21.5 - 21.8)
--------------	--------------	-------------------------------------

Supplemental Table 8 Substance use disorder and Diabetes Mellitus-related Age-Adjusted Mortality Rates per 1000,000 Stratified by Urban-Rural Classification in Adults in the United States from 1999 to 2020

Age-Adjusted Mortality Rate (95%CI)		
Year	Metropolitan	Nonmetropolitan
1999	11.9 (11.3 - 12.5)	11.4 (10.5 - 12.4)
2000	12.3 (11.7 - 12.9)	12.2 (11.2 - 13.2)
2001	12.6 (12.0 - 13.2)	13.0 (12.0 - 14.0)
2002	14.0 (13.3 - 14.6)	14.0 (13.0 - 15.1)

2003	14.4 (13.8 - 15.0)	15.9 (14.8 - 17.0)
2004	15.3 (14.7 - 16.0)	16.6 (15.5 - 17.8)
2005	16.3 (15.6 - 17.0)	17.9 (16.7 - 19.1)
2006	17.3 (16.6 - 18.0)	18.4 (17.2 - 19.5)
2007	18.2 (17.5 - 18.9)	20.0 (18.8 - 21.2)
2008	17.8 (17.1 - 18.4)	19.5 (18.3 - 20.7)
2009	18.2 (17.5 - 18.9)	19.7 (18.6 - 20.9)
2010	18.9 (18.3 - 19.6)	21.6 (20.3 - 22.8)
2011	19.8 (19.1 - 20.4)	22.1 (20.8 - 23.3)

2012	20.2 (19.6 - 20.9)	23.2 (21.9 - 24.5)
2013	21.7 (21.0 - 22.4)	23.4 (22.1 - 24.7)
2014	22.9 (22.2 - 23.6)	25.0 (23.7 - 26.4)
2015	23.1 (22.4 - 23.8)	28.1 (26.6 - 29.5)
2016	25.2 (24.5 - 25.9)	30.0 (28.6 - 31.5)
2017	27.2 (26.4 - 27.9)	32.9 (31.4 - 34.5)
2018	28.5 (27.8 - 29.3)	36.7 (35.0 - 38.3)
2019	30.6 (29.8 - 31.4)	39.9 (38.2 - 41.7)

2020	39.2 (38.3 - 40.2)	50.4 (48.5 - 52.4)
------	-----------------------	-----------------------

95% CI= 95% Confidence Interval

Supplemental Table 9 Annual reported deaths due to substance use disorder and Diabetes Mellitus, stratified by substance use disorder

Deaths						
Years	Opioid use	Intentional substance overdose	Stimulant use	Alcohol use	Sedative hypnotics use	Cocaine use
1999	85	61	14	1678	30	140
2000	92	71	21	1801	28	126
2001	89	75	13	1873	24	150
2002	151	76	40	2037	36	181
2003	178	88	44	2133	43	220
2004	183	78	61	2294	45	239
2005	242	92	76	2427	65	297
2006	289	113	63	2612	55	331
2007	315	128	78	2767	79	346
2008	330	112	63	2812	77	303
2009	379	119	99	2886	93	272
2010	450	136	122	3100	128	273
2011	454	118	130	3181	149	283
2012	503	135	196	3355	146	287

2013	586	157	264	3522	161	297
2014	640	172	339	3712	185	336
2015	653	159	408	3971	182	347
2016	794	172	515	4200	218	431
2017	855	165	665	4549	258	545
2018	913	174	782	4907	272	583
2019	945	199	994	5243	253	677
2020	1322	203	1347	6801	312	786
Total	10448	2803	6334	71861	2839	7450

Supplemental Table 10 Codes for Substance use

E24.4 (Alcohol-induced pseudo-Cushing syndrome)

F10 (Mental and behavioural disorders due to use of alcohol)

G31.2 (Degeneration of nervous system due to alcohol)

G62.1 (Alcoholic polyneuropathy)

G72.1 (Alcoholic myopathy)

I42.6 (Alcoholic cardiomyopathy)

K70 (Alcoholic liver disease)

K85.2 (Alcohol-induced acute pancreatitis)

K86.0 (Alcohol-induced chronic pancreatitis)

R78.0 (Finding of alcohol in blood)

T51 (Toxic effect of alcohol)

X65 (Intentional self-poisoning by and exposure to alcohol)

Y15 (Poisoning by and exposure to alcohol, undetermined intent)

F11 (Mental and behavioural disorders due to use of opioids)

F12 (Mental and behavioural disorders due to use of cannabinoids)

F13 (Mental and behavioural disorders due to use of sedatives or hypnotics)

F14 (Mental and behavioural disorders due to use of cocaine)

F15 (Mental and behavioural disorders due to use of other stimulants, including caffeine)

F16 (Mental and behavioural disorders due to use of hallucinogens)

F18 (Mental and behavioural disorders due to use of volatile solvents)

F19 (Mental and behavioural disorders due to multiple drug use and use of other psychoactive substances)

R78.1 (Finding of opiate drug in blood)

R78.2 (Finding of cocaine in blood)

R78.3 (Finding of hallucinogen in blood)

R78.4 (Finding of other drugs of addictive potential in blood)

T42.3 (Barbiturates)

T42.4 (Benzodiazepines)

T42.6 (Other antiepileptic and sedative-hypnotic drugs)

T42.7 (Antiepileptic and sedative-hypnotic drugs, unspecified)

T43.6 (Psychostimulants with abuse potential)

X61 (Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified)

X62 (Intentional self-poisoning by and exposure to narcotics and psychodysleptics [hallucinogens], not elsewhere classified)

X64 (Intentional self-poisoning by and exposure to other and unspecified drugs, medicaments and biological substances)

X66 (Intentional self-poisoning by and exposure to organic solvents and halogenated hydrocarbons and their vapours)

Y11 (Poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified, undetermined intent)

Y12 (Poisoning by and exposure to narcotics and psychodysleptics [hallucinogens], not elsewhere classified, undetermined intent)

Y14 (Poisoning by and exposure to other and unspecified drugs, medicaments and biological substances, undetermined intent)

Y16 (Poisoning by and exposure to organic solvents and halogenated hydrocarbons and their vapours, undetermined intent)

T52 (Toxic effect of organic solvents)

T53 (Toxic effect of halogen derivatives of aliphatic and aromatic hydrocarbons)

T50.9 (Other and unspecified drugs, medicaments and biological substances)

Categories

Opioids

F11 (Mental and behavioural disorders due to use of opioids)

R78.1 (Finding of opiate drug in blood)

T40.0 (Opium)

T40.1 (Heroin)

T40.2 (Other opioids)

T40.3 (Methadone)

T40.4 (Other synthetic narcotics)

T40.6 (Other and unspecified narcotics)

Y12 (Poisoning by and exposure to narcotics and psychodysleptics [hallucinogens], not elsewhere classified, undetermined intent)

Cannabis

F12 (Mental and behavioural disorders due to use of cannabinoids)

T40.7 (Cannabis (derivatives))

Cocaine

F14 (Mental and behavioural disorders due to use of cocaine)

R78.2 (Finding of cocaine in blood)

T40.5 (Cocaine)

Sedative, hypnotics

F13 (Mental and behavioural disorders due to use of sedatives or hypnotics)

T42.3 (Barbiturates)

T42.4 (Benzodiazepines)

T42.6 (Other antiepileptic and sedative-hypnotic drugs)

T42.7 (Antiepileptic and sedative-hypnotic drugs, unspecified)

X61 (Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified)

Y11 (Poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified, undetermined intent)

Alcohol

E24.4 (Alcohol-induced pseudo-Cushing syndrome)

F10 (Mental and behavioural disorders due to use of alcohol)

G31.2 (Degeneration of nervous system due to alcohol)

G62.1 (Alcoholic polyneuropathy)

G72.1 (Alcoholic myopathy)

I42.6 (Alcoholic cardiomyopathy)

K70 (Alcoholic liver disease)

K85.2 (Alcohol-induced acute pancreatitis)

K86.0 (Alcohol-induced chronic pancreatitis)

R78.0 (Finding of alcohol in blood)

T51 (Toxic effect of alcohol)

X65 (Intentional self-poisoning by and exposure to alcohol)

Y15 (Poisoning by and exposure to alcohol, undetermined intent)

Stimulants

F15 (Mental and behavioural disorders due to use of other stimulants, including caffeine)

T43.6 (Psychostimulants with abuse potential)

Intentional substance overdose

X61 (Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified)

X62 (Intentional self-poisoning by and exposure to narcotics and psychodysleptics [hallucinogens], not elsewhere classified)

X64 (Intentional self-poisoning by and exposure to other and unspecified drugs, medicaments and biological substances)

X66 (Intentional self-poisoning by and exposure to organic solvents and halogenated hydrocarbons and their vapours)

X61 (Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified)

X62 (Intentional self-poisoning by and exposure to narcotics and psychodysleptics [hallucinogens], not elsewhere classified)

X64 (Intentional self-poisoning by and exposure to other and unspecified drugs, medicaments and biological substances)

X66 (Intentional self-poisoning by and exposure to organic solvents and halogenated hydrocarbons and their vapours)

Y11 (Poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified, undetermined intent)

Y12 (Poisoning by and exposure to narcotics and psychodysleptics [hallucinogens], not elsewhere classified, undetermined intent)

Y14 (Poisoning by and exposure to other and unspecified drugs, medicaments and biological substances, undetermined intent)

Y16 (Poisoning by and exposure to organic solvents and halogenated hydrocarbons and their vapours, undetermined intent)
